CURRICULUM VITAE
Christopher Chitambar MBBS
Christopher Chitambar MBBS
Emeritus Professor
Department of Biophysics
Department of Biophysics
OFFICE ADDRESS: |
8701 Watertown Plank Road |
Milwaukee, WI 53226 |
EDUCATION: |
1969 - Present Jumna Christian College, Allahabad, India |
1971 - Present BS, Ewing Christian College, Allahabad, India |
1975 - Present MBBS, Christian Medical College, Punjab University, Ludhiana, India |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
1975 - 1976 Rotating Intern, Christian Medical College, Ludhiana, India |
1977 - 1980 Resident, Internal Medicine, Central Texas Medical Foundation at Brackenridge Hospital, Austin, TX |
1980 - 1983 Fellow, Hematology/Oncology, University of Colorado Health Sciences Center, Denver, CO |
FACULTY APPOINTMENTS: |
1983 - 1984 Instructor in Medicine, University of Colorado Health Sciences Center, CO |
1984 - 1989 Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI |
1989 - 1996 Associate Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI |
1996 - Present Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI |
2000 - 2001 Acting Co-Chief, Hematology/Oncology Division, Medical College of Wisconsin, Milwaukee, WI |
2000 - Present Director, Hematology/Oncology Fellowship Program, Medical College of Wisconsin, Milwaukee, WI |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
1975 - 1976 Rotating Intern, Christian Medical College, Ludhiana, India |
1977 - 1980 Resident in Internal Medicine, Central Texas Medical Foundation at Brackenridge Hospital, Austin, TX |
1980 - 1983 Fellow in Hematology/Oncology, University of Colorado Health Sciences Center, Denver, CO |
HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS: |
1981 - 1984 Part-time Physician, Walk In Clinic, Denver General Hospital, Denver, CO |
1982 - 1983 Part-time Emergency Room Physician, Denver V.A. Hospital, Denver, CO |
1984 - Present Staff, Froedtert Memorial Lutheran Hospital (teaching hospital of the Medical College of Wisconsin), John L. Doyne Hospital, Milwaukee, WI |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Internal Medicine | 1980 | None |
Subspecialty Board in Hematology | 1982 | None |
Subspecialty Board in Medical Oncology | 1983 | None |
Licensure | Number | Issue Date | Expiration |
Iowa License | 25911 | None | |
Wisconsin License | 25911 | None | |
AWARDS AND HONORS: |
1972 - Present Scholarship Award , Panjab University |
1996 - Present Best Doctors in America: Midwest Region Directory |
1999 - Present Fellowship in the American College of Physicians, American Society of Internal Medicine |
2001 - 2002 Best Doctors in America |
2003 - 2010 America’s Top Doctors, Castle Connolly Medical |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
American Society of Hematology (Member) |
American Society of Clinical Oncology (Member) |
American Association for Cancer Research (Member) |
American Association for the Advancement of Science (Member) |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Journal Review |
Blood |
Proc. Natl. Acad Sci. USA |
Life Sciences |
Journal of Investigative Dermatology |
American Journal of Physiology |
Biochchimica et Biophysica Acta (BBA) |
Biochemistry |
Radiation Research |
Cancer Research |
Critical Reviews in Oncology/Hematology |
Cancer Immunology Immunotherapy |
British J. of Pharmacology |
American Journal of Physiology |
Drugs |
American Journal of Pathology |
Cell and Tissue Kinetics |
International Journal of Radiation Biology |
Clinical Cancer Research |
Free Radical Biology & Medicine |
Clinical Lymphoma |
Current Medicinal Chemistry |
Journal of Cellular Physiology |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
1988 - 1992 Member, Board of Trustees, Leukemia Society of America, Wisconsin Chapter |
1988 - 1989 Member, Medical Advisory Committee, Blood Center of Southeastern Wisconsin |
06/1995 Participant, Relay for Life, American Cancer Society |
06/22/1996 Participant, and Speaker, Relay for Life, American Cancer Society |
08/22/1998 - Present Speaker, Bone Marrow Transplant Support Group, Leukemia Society of America, Wisconsin Chapter |
01/30/2010 - Present Invited Speaker, Hope in the Face of Breast Cancer, St. Mathew’s Church |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
Metal treatment for recurrent lymphoma – Does gallium have a role?, Lymphoma…The Next Questions. International Conference, San Juan, Puerto Rico, 04/24/2003 - 04/25/2003 |
Gallium compounds for the treatment of malignancy: Identification of molecular targets for antineoplastic activity and drug resistance, Australian Society for Medical Research, 42nd National Scientific Conference, Adelaide, Australia, 11/23/2003 - Present |
Gallium compounds for the treatment of malignancy. Targeting iron-dependent tumor growth and beyond, Children’s Cancer Institute Australia Conference, Sydney, Australia, 11/26/2003 - Present |
National |
Therapeutic Approaches to Management of the Discussant Participant: Metabolic Complications of Cancer (Role of Gallium nitrate in the Treatment of Hypercalcemia), Round Table Symposium, Laguna Beach, CA, 10/1990 - Present |
Modulation of Leukemic Cell Growth Through Perturbation of Cellular Iron Metabolism, City of Hope Medical Center, Duarte, CA, 06/06/1991 - Present |
Clinical Aspects of Bcl-2 Antisense and Other Apoptosis-based Therapies, Symposium in conjunction with American Society of Hematology Annual Meeting, San Diego, CA, 12/05/2003 - Present |
Current Trends in Leukemia, Lymphoma, and Myeloma, Washington, DC, 02/28/2004 - Present |
Clinical Strategies to Induce Apoptosis in Tumors, Symposium in conjunction with American Society for Clinical Oncology annual meeting, New Orleans, LA, 06/08/2004 - Present |
Regional |
Transferrin Receptor Expression & Effects of Transferrin-Gallium on Leukemic Cells, Hematology-Oncology Research Seminar, Indiana University School of Medicine, 11/1984 - Present |
Effects of Transferrin-Gallium on Hematopoiesis, Hematology-Oncology Research Seminar, Indiana University School of Medicine, 11/1986 - Present |
Chronic leukemias, St. Therese Hospital, Waukegan, IL, 04/28/1993 - Present |
Targeting iron-dependent tumor cell growth with gallium: Mechanisms of cytotoxicity and drug resistance, Hematology/Oncology Grand Rounds, University of Iowa Hospitals and Clinics, 11/20/1996 - Present |
Targeting Iron Dependent Tumor Cell Growth with Gallium: Basic Mechanisms of Cytotoxicity and Drug Resistance, Cancer Center Seminar, Indiana University School of Medicine, 09/01/1999 - Present |
Hemochromatosis, Dept. of Medicine Grand Rounds, Indiana University School of Medicine, 09/01/1999 - Present |
American College of Physicians/American Society of Internal Medicine: Preparation for Board Re-certification course, Hematology/Oncology Session, Chicago, IL, 10/12/2001 - 10/14/2001 |
Innovations in Lymphoma Treatments, Trial of gallium nitrate for the treatment of refractory non-Hodgkin’s lymphoma, Chicago, IL, 06/15/2002 - Present |
American College of Physicians/American Society of Internal Medicine: Preparation for Board Re-certification course, Hematology/Oncology session, Chicago, IL, 10/2002 - Present |
Induction of Apoptosis by Gallium-containing Small Molecules: Mechanisms of Action and Clinical Application, Direct Targeting of Apoptosis in Cancer Treatment, Chicago, IL, 05/30/2003 - Present |
American College of Physicians/American Society of Internal Medicine: Preparation for Board Re-certification course Postgraduate course 0313, Hematology/Oncology session, Chicago, IL, 10/10/2003 - 10/11/2003 |
Iron-dependent Tumor Growth as a target for treatment of lymphoma: A role for gallium compounds, Division of Hematology Grand Rounds, Rush University Medical Center, Chicago, IL, 02/03/2004 - Present |
Iron-dependent Tumor Growth as a Target for Treatment of Lymphoma, Division of Hematology/Oncology Grand Rounds, Loyola University Cancer Center, Chicago, IL, 06/11/2004 - Present |
American College of Physicians preparation for re-certification course # PG0414and Oncology session, Hematology and Oncology session, Chicago, IL, 10/14/2004 - 10/16/2004 |
Iron Proteins as Novel Targets for the Treatment of non-Hodgkin’s Lymphoma. A role for gallium compounds, Robert H. Lurie Cancer Center, Northwestern University Medical School, Chicago IL, 03/03/2005 - Present |
American College of Physicians preparation for re-certification course # PG0504, Hematology and Oncology session, Chicago, IL, 10/06/2005 - 10/09/2005 |
American College of Physicians. Maintenance of certification course for Internal Medicine, Hematology and Oncology session, Schaumberg IL, 10/11/2007 - 10/14/2007 |
American College of Physicians. Maintenance of certification course for Internal Medicine, Hematology and Oncology session, Chicago, IL, 10/02/2009 - Present |
American College of Physicians. Maintenance of certification course for Internal Medicine, Hematology and Oncology session, Chicago, IL, 10/01/2010 - Present |
Local |
Leukemic Cell Differentiation, Hematology/Oncology Conference, Medical College of Wisconsin, Milwaukee, WI, 07/1985 - Present |
Transferrin Receptor Expression and Effects of Transferrin-Metals on Leukemic Cells, Cell and Molecular Biology Seminar, Medical College of Wisconsin, Milwaukee, WI, 11/1985 - Present |
Anemia in the Elderly, Dept. of Medicine Conference, VA Hospital, John Doyne Hospital and St. Joseph's Hospital, 1985 - Present |
Regulation of the Transferrin Receptor, Biophysics course on receptors, Medical College of Wisconsin, Milwaukee, WI, 01/1986 - Present |
Plasma Cell Disorders, Dept. of Medicine Conference, Medical College of Wisconsin, Milwaukee, WI, 06/1986 - Present |
Discussant, Clinical Path Conference, Medical College of Wisconsin, Milwaukee, WI, 10/1986 - Present |
Hemolytic Anemias, Dept. of Medicine Conference, 04/1987 - Present |
Iron Metabolism and Leukemic Cell Proliferation, Bone Marrow Transplantation Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 07/1987 - Present |
Proteins of Iron Transport, Biophysics course on metals, Medical College of Wisconsin, Milwaukee, WI, 03/1988 - Present |
The Transferrin Receptor, Blood Center of Southeastern Wisconsin, Milwaukee, WI, 04/28/1988 - Present |
The Emerging Role of Hematopoietic Growth Factors in Clinical Medicine, Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 09/28/1988 - Present |
Grand Rounds Lecture on "Leukemia", Memorial Hospital, Oconomowoc, WI, 08/16/1991 - Present |
Bone Marrow Transplantation, 1991, Fourth Annual Update in Primary Care Course, Medical College of Wisconsin, Milwaukee, WI, 09/27/1991 - Present |
Interactions of Gallium and Iron in Proliferating Cells, Colloquium Speaker, Department of Chemistry, University of Wisconsin, Milwaukee, WI, 09/21/1992 - Present |
Gallium Nitrate for the Treatment of Medulloblastoma, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, 10/30/1992 - Present |
Molecular Techniques in Research, University of Wisconsin, Milwaukee, WI, 06/27/1994 - 07/16/1994 |
Patient with abdominal mass and hypogammaglobulinemia, Clinical Path Conference, Medical College of Wisconsin, Milwaukee, WI, 04/13/1995 - Present |
Thrombotic Thrombocytopenic Purpura, Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 10/13/1995 - Present |
Leukemia and Bone Marrow Transplantation, Mini Medical School Series, Medical College of Wisconsin, Milwaukee, WI, 03/19/1996 - Present |
Chronic Lymphocytic Leukemia, Grand Rounds, West Allis Hospital, Milwaukee, WI, 03/04/1997 - Present |
Targeting iron-dependent malignant cell growth with gallium: Mechanisms of cytotoxicity and drug resistance, Academic Conference, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 03/21/1997 - Present |
Leukemia and Bone Marrow Transplantation, Mini Medical School Series, Medical College of Wisconsin, Milwaukee, WI, 04/15/1997 - Present |
Leukemia: Cancer of the Blood, Mini Medical School, Understanding Cancer Series, Medical College of Wisconsin, Milwaukee, WI, 11/04/1997 - Present |
Development of gallium as a chemotherapeutic agent. Mechanisms of cytotoxicity and drug resistance, Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 01/15/1998 - Present |
Faculty in Hematology/Oncology for the American College of Physicians/American Society of Internal Medicine, Preparation for Re-certification using the MKSAP-11 Program, Milwaukee, WI, 10/16/1998 - 10/19/1998 |
Acute Porphyria, Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 03/12/1999 - Present |
American College of Physicians/American Society of Internal Medicine: Preparation for Board Re-certification course, Hematology/Oncology session, Milwaukee, WI, 10/01/1999 - 10/03/1999 |
American College of Physicians/American Society of Internal Medicine: Preparation for Board Re-certification course, Hematology/Oncology Session, Milwaukee, WI, 09/2000 - Present |
Chemotherapeutic and hormonal approaches to breast cancer treatment, Breast Cancer: A Family’s Journey, Mount Mary College, Milwaukee, WI, 11/10/2001 - Present |
Diagnosis and Management of non-Hodgkin’s Lymphoma, Symposium for Senior Physicians, Medical College of Wisconsin, Milwaukee, WI, 10/08/2003 - Present |
Diagnosis and Management of non-Hodgkin’s Lymphoma, Symposium for Senior Physicians, Medical College of Wisconsin, Milwaukee, WI, 10/08/2003 - Present |
Targeted Therapy for Lymphoma, Department of Medicine Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 06/18/2004 - Present |
Iron-dependent Tumor Growth as a Target for Treatment of Lymphoma, University of Wisconsin Cancer Center, Madison, WI, 07/14/2004 - Present |
Review of the peripheral blood smear in the diagnosis of hematologic disease, Internal Medicine Core Skills Program for Residents. Internal Medicine 101, Medical College of Wisconsin, Milwaukee, WI, 2004 - 2005 |
After Breast Cancer Diagnosis (ABCD) Mentor Continuing Education Program, Update on hormonal treatment for Breast Cancer, 01/29/2005 - Present |
Internal Medicine 301, Internal Medicine Board Preparation Course for Residents, Medical College of Wisconsin, Milwaukee, WI, 05/2006 - Present |
Review of the peripheral blood smear in the diagnosis of hematologic disease, Internal Medicine Core Skills Program for Residents. Internal Medicine 101, Medical College of Wisconsin, Milwaukee, WI, 08/2006 - 09/2006 |
American College of Physicians preparation for re-certification course for Internal Medicine, Hematology and Oncology session, Chicago, IL, 10/05/2006 - 10/08/2006 |
Update on chemotherapy and novel targeted agents in metastatic breast cancer, Best Practices in Oncology Advances in Breast Cancer 2006, Milwaukee, WI, 11/07/2006 - Present |
Educational Core Competency Skills – Phase III, Hematology and Oncology session, Medical College of Wisconsin, Milwaukee, WI, 03/2007 - 04/2007 |
Educational Core Competency Skills – Phase 1, Hematology and Oncology session, Medical College of Wisconsin, Milwaukee, WI, 08/2007 - 10/2007 |
The Evolution of the Cancer Cell – Why is it so hard to treat?, Community Education Talk, 11/15/2007 - Present |
Residency Educational Core Competency Skills, Phase III, Hematology and Oncology session, Medical College of Wisconsin, Milwaukee, WI, 03/2008 - 05/2008 |
Update on adjuvant treatment for breast cancer, 10th Annual Women’s Health Conference, Milwaukee, WI, 04/25/2008 - Present |
Medical Neoplasia, Important Clinical Advances, Alumni Day for Medical College of Wisconsin and Marquette University, Milwaukee, WI, 05/03/2008 - Present |
Preparing for Fellowship and ABIM Boards, American College of Physicians Wisconsin Chapter Scientific Meeting, Wisconsin Dells, WI, 09/13/2008 - Present |
American College of Physicians. Maintenance of certification course for Internal Medicine, Hematology and Oncology session, Chicago IL, 10/01/2008 - Present |
Iron-dependent tumor growth as a therapeutic target in cancer treatment, Multidisciplinary Research Conference, Medical College of Wisconsin, Milwaukee, WI, 05/11/2010 - Present |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
1985 - 2001 Member, Research Grants Review Committee, Cancer Center, Medical College of Wisconsin |
1986 - 1988 Member, Thesis Advisory Committee, Department of Pathology, Medical College of Wisconsin |
1987 - 1993 Member, Medical Care Evaluation Committee, Milwaukee County Medical Complex, Medical College of Wisconsin |
1987 - 1991 Director, Fellowship Program, Hematology/Oncology Division, Medical College of Wisconsin |
1988 - 1992 Member, Executive Committee, Cancer Center, Medical College of Wisconsin |
1988 - 1993 Chairman, Research Review Committee, Carcinogen Subcommittee, Medical College of Wisconsin |
1988 - 1990 Program Leader, Cancer Biology Group, Cancer Center, Medical College of Wisconsin |
1990 - 1992 Member, Thesis Advisory Committee, Biophysics Program, Medical College of Wisconsin |
1993 - 2003 Member, Student Summer Research Fellowship Program Committee, Medical College of Wisconsin |
1993 - 2003 Member and Secretary, Laboratory Safety Committee, Medical College of Wisconsin |
1993 - 1996 Member, Research Affairs Committee, Medical College of Wisconsin |
1993 - 2004 Member, Clinical Research Center (CRC) Review Committee, Medical College of Wisconsin |
1994 - 1997 Member, Thesis Advisory Committee, Department of Biochemistry, Medical College of Wisconsin |
1995 - 1996 Member, Thesis Advisory Committee, Department of Chemistry, University of Wisconsin, Milwaukee |
1997 - 1998 Member, Service Standards (Goals) Committee, Medical College of Wisconsin |
1997 - Present Member, Physician Credentialing Committee, Medical College of Wisconsin |
1999 - 2000 Chairman of Dermatology, Search Committee, Medical College of Wisconsin |
1999 - 2004 Chair, General Clinical Research Center Review Committee, Medical College of Wisconsin |
2000 - Present Member, Faculty Development Committee, Dept. of Medicine, Medical College of Wisconsin |
2000 - Present Director, Hematology/Oncology Fellowship Program, Medical College of Wisconsin |
2003 - Present Reviewer and referee, Ph.D Thesis, University of New South Wales, Australia |
2004 - 2005 Member, Search Committee for Director of the General Clinical Research Center, Medical College of Wisconsin |
2006 - Present Member, Allied Health Professionals Credentialing Committee, Medical College of Wisconsin |
2007 Chairman of Dermatology, Search Committee, Medical College of Wisconsin |
2008 - Present Member, Steering Committee, Breast Cancer Program MCW& FMLH Clinical Cancer Center, Medical College of Wisconsin |
Member, Cancer Center, Clinical Research Program, Medical College of Wisconsin |
Member, Cancer Center, Medical College of Wisconsin |
EXTRAMURAL TEACHING: |
Community/Lay Public |
Hematology/Oncology , Teaching clinical case management (junior syllabus) to junior medical students. |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Undergraduate Students |
06/2005 - 07/2005 Dianah V. Marable, Project – Analysis of the antiproliferative activity of gallium maltolate, a novel gallium compound, in lymphoma cell lines, Medical College of Wisconsin |
Medical Students |
1992 Sonali Desai, Second Year Medical Student Summer Research Project. “Action of gallium on melanoma cells”, Medical College of Wisconsin |
1999 - 2000 Steve Sadicario, Advisor/Preceptor, Medical College of Wisconsin |
2004 - 2005 Paul Jimenez, Advisor/Preceptor, Medical College of Wisconsin |
2009 - Present Jill Daubner, Master Clinician Preceptor, Medical College of Wisconsin |
Graduate Students |
Students Advised |
1989 - 1992 Jana Narasimhan, Effects of copper and gallium compounds on ribonucleotide reductase, Medical College of Wisconsin |
PhD Committees |
Ching-Fang Chang, Department of Biophysics, Medical College of Wisconsin |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Undergraduate Students |
1988 - 1989 Melissa Jurica |
1993 Pamela Boon |
1995 - Present Sreedevi Nyayapati, Department of Chemistry, University of Wisconsin, Milwaukee |
06/1996 - 08/1996 Sharnecia Harris |
06/1998 - 08/1998 Shenell Y. Miller, Studies of inhibitors of ribonucleotide reductase on the growth of human bladder cancer and head and neck cancer cells |
Medical Students |
02/1995 - 07/1995 Pamela Boon, Minority Summer Research Training. Projects: "Transferrin receptor regulation in human umbelical vein endothelial cells" & "Studies of Gallium-PIH, a novel gallium complex with antineoplastic activity |
05/1996 - 08/1996 Michael Myette, "Evaluation of drug synergy between gallium nitrate and novel inhibitors of ribonucleotide reductase". |
05/1997 - 08/1997 Gregory Knorr, Evaluation of the mechanism of Gallium-PIH as an antineoplastic agent |
06/1997 - 07/1997 Michael Myette, Studies of the antinneoplastic activity of Gemcitabine in ribonucleotide reductase-overproducing cells |
08/1999 - 2000 Dena Green, M.D., Mechanisms of Apoptosis induced by iron chelators |
Postdoctoral Researchers |
07/1995 - 12/1996 Stuart Wong, M.D., "Ribonucleotide reductase expression in hematologic malignancies." |
07/2004 - 12/2004 Thomas Joseph, M.D., Inhibition of mantle cell lymphoma with gallium compounds. Synergistic interaction with bortezomib |
07/2005 - 11/2005 Thomas Joseph, M.D., Inhibition of mantle cell lymphoma with gallium compounds. Synergistic interaction with bortezomib |
01/2007 - 06/2007 Mohamed Ahmed, MD, PhD, Effects of gallium compounds on mitochondrial function |
02/2008 - 06/2008 Santosh Gowda, MD |
Stuart Wong, M.D. |
Clinical/Research Fellows |
1987 - 1988 William Matthaeus, M.D. |
1989 - 1990 Joel Lundberg, Project: Interaction of gallium with iron chelators and fludarabine |
07/1997 - 06/1998 Stuart Wong, M.D., Ribonucleotide reductase expression in hematologic malignancies |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Chitambar CR, Robinson WA, and Glode LM: Familial leukemia and aplastic anemia associated with monosomy 7. American Journal of Medicine 75:756-762, l983. |
2. Chitambar CR, Massey EJ, and Seligman PA: Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation: effects of gallium and dimethyl sulfoxide. Journal of Clinical Investigation 72:l3l4-l325, l983. |
3. Chitambar CR and Seligman PA: Effect of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of transferrin-gallium. Journal of Clinical Investigation 78:l538-l546, l986. |
4. Chitambar CR and Zivkovic Z: Inhibition of hemoglobin production by transferrin-gallium. Blood 69:l44-l49, l987. |
5. Chitambar CR and Zivkovic Z: Uptake of Gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Cancer Research 47:3929-3934, l987. (This work was cited in the Year Book of Nuclear Medicine, 1988). |
6. Bufill JA, Lum LG, Caya JG, Chitambar CR, Ritch PS, Anderson T, and Ash RC: Pityrosporum folliculitis in bone marrow transplant recipients: Clinical observations in five patients. Annals of Internal Medicine 108:560-563, 1988. |
7. Seligman PA, Chitambar CR, Vostrejs M and Moran PL: The effects of various transferrins on iron utilization by proliferating cells. Annals New York Academy of Sciences 526:136-140, 1988. |
8. Hansen R, Quebbeman E, Ritch P, Chitambar C, and Anderson T: Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: A phase II study. American Journal of Medical Science 295 (2): 91-93, 1988. |
9. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chitambar C, and Vukelich M*: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. American Journal of Clinical Oncology 11:461-464, 1988. |
10. Bunin NJ, Casper JT, Chitambar C, Hunter J, Truitt R, Menitove J, Camitta B, and Ash RC: Partially matched marrow transplantation in patients with myelodysplastic syndromes. Journal of Clinical Oncology 6:1851-1855, 1988. |
11. Chitambar CR, Matthaeus WG*, Antholine WE, Graff K, and O'Brien WJ: Inhibition of leukemic HL60 cell growth by transferrin-gallium: Effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72:1930-1936, 1988. |
12. Chitambar CR, Craig, A, and Ash RC: Transferrin receptor-mediated suppression of in vitro hematopoiesis by transferrin-gallium. Experimental Hematology 17:418-422, 1989. |
13. Chitambar CR, Seigneuret MC, Matthaeus, WG and Lum LG: Modulation of lymphocyte proliferation and immunoglobulin production by transferrin-gallium. Cancer Research 49:1125-1129, 1989. |
14. Chitambar CR, and Zivkovic, Z: Release of soluble transferrin receptor from the surface of human leukemic HL60 cells. Blood 74:602-608, 1989. |
15. Chitambar CR, and Zivkovic-Gilgenbach Z: Role of the acidic receptosome in the uptake and retention of gallium-67 by human leukemic HL60 cells. Cancer Research 50:1484-1487, 1990. |
16. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA, Gottshall JL, Oldham K, Anderson T, Camitta B, and Menitove J: Successful allogeneic marrow transplantation from closely HLA-matched unrelated donors using T-cell depletion. New England Journal of Medicine 322:485-94, 1990. |
17. Chitambar CR, Zivkovic-Gilgenbach Z, Narasimhan J, and Antholine WE: Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. Cancer Research 50:4468-4472, 1990. |
18. Chitambar CR, and Zivkovic-Gilgenbach Z: Influence of cellular iron status on the release soluble transferrin receptor from human promyelocytic leukemic HL60 cells. Journal of Laboratory & Clinical Medicine 116:345-353, 1990. |
19. Lundberg JL, and Chitambar CR: Interaction of gallium nitrate, fludarabine and iron chelators: Effects on the proliferation of human leukemic HL60 cells. Cancer Research 50:6466-6470, 1990. |
20. Chitambar CR, Libnoch J, Matthaeus WG, Ash RC, Ritch PS and Anderson T: Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. American Journal of Hematology 37:100-104, 1991. |
21. Weissman DE, Janjan NA, Erickson B, Wilson JF, Greenberg M, Ritch PS, Anderson T, Chitambar CR, Lawton C, and Rousey SR. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. Journal of Neuro-Oncology 11:235-239,1991. |
22. Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, and Ash RC: Allogeneic marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. Journal of Clinical Oncology 9:1848-1859, 1991. |
23. Chitambar CR, and Narasimhan J: Targeting iron-dependent DNA synthesis with gallium and transferrin-gallium. Pathobiology. Journal of Immunopathology, Molecular, and Cellular Biology 59:3-10, 1991. |
24. Whelan HT, Przybylski C, and Chitambar CR: Differential effects of gallium nitrate on the proliferation of human brain tumor cells in vitro. Pediatric Neurology 7:23-27, 1991. |
25. Chitambar CR, Loebel AL, and Noble NA: Shedding of transferrin receptor from rat reticulocytes during maturation in vitro: soluble transferrin receptor is derived from receptor shed in vesicles. Blood 78:2444-2450, 1991. |
26. Narasimhan J, Antholine WE, Chitambar CR, and Petering DH: Inhibition of iron uptake in HL60 cells by 2-formyl pyridine monothiosemicarbazonato Cu(II). Archives of Biochemistry and Biophysics 289:393-398, 1991. |
27. Whelan HT, Przybylski C, and Chitambar CR: Alteration of DNA synthesis in human brain tumor cells by gallium nitrate in vitro. Pediatric Neurology 7:352-354, 1991. |
28. Chitambar CR, Narasimhan J, Guy J, Sem DS, and O'Brien WJ: Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Research. 51:6199-6201, 1991. |
29. Chitambar CR, and Sax D: Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. Blood 80:505-511, 1992. |
30. Narasimhan J, Antholine WE, and Chitambar CR: Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase. Biochemical Pharmacology 44:2403-2408, 1992. |
31. Whelan HT, Schmidt MC, Anderson GS, Chan BK, Kubacki D, Segura AD, and Chitambar CR: Antineoplastic effects of gallium nitrate on human medulloblastoma in vivo. Pediatric Neurology 8:323-327, 1992. |
32. Rhodes JC, Jensen HE, Nilius AM, Chitambar CR, Farmer SG, Washburn RG, Steele PE, and Amlung TW: Aspergillus and Aspergillosis. Journal of Medical and Veterinary Mycology Supp. 1. 30:51-57, 1992. |
33. Haq RU and Chitambar CR: Modulation of transferrin receptor mRNA by transferrin-gallium in human myeloid and lymphoid cells. Biochemical Journal 294:873-877, 1993. |
34. Whelan HT, Williams MB, Bajic D, Sequra A, McAuliffe TL, and Chitambar CR: The prevention of gallium toxicity by hyperhydration in the treatment of medulloblastoma. Pediatric Neurology 10:217-220, 1994. |
35. Chitambar CR, Wereley JP, and Haq RU: Synergistic inhibition of T lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human interferon-alpha through action on cellular iron uptake. Cancer Research 54:3224-3228, 1994. |
36. Drobyski, WR, Ash RC, Casper JT, McAuliffe, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T, and Flomenberg N: Effect of T-cell depletion as graft-versus-host prophylaxis on engraftment, relapse and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980-1987, 1994. |
37. Whelan HT, Williams MB, Bajic DM, Flores RE, Schmidt MH, McAuliffe TL, and Chitambar CR: Gallium nitrate delays the progression of microscopic disease in a human medulloblastoma murine model. Pediatric Neurology,11:44-46,1994. |
38. Haq RU, Wereley JP and Chitambar CR: Induction of apoptosis by iron deprivation in human Lymphoid leukemic CCRF-CEM cells. Experimental Hematology 23:428-432, 1995. |
39. Chitambar CR and Wereley JP: Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: Changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. Cancer Research, 55:4361-4366, 1995. |
40. Chitambar CR, Boon P, and Wereley JP: Evaluation of transferrin and gallium-isonicotinoyl hydrazone (Ga-PIH) as potential therapeutic agents to overcome leukemic cell resistance to gallium. Clinical Cancer Research, 2:1009-1015, 1996. |
41. Drobyski WR, Haq RU, Majewski D, Chitambar CR. Modulation of in vitro and in vivo T cell responses by transferrin-gallium and gallium nitrate. Blood 88:3056-3064, 1996. |
42. Akansel G, Liu Y, Chitambar CR, Kitapci MT, Akansel S, Krasnow AZ, Isitman A, Collier BD. Effect of gallium nitrate therapy on gallium-67 scintigraphic detection of lymphoma: Report of a case. Clinical Nuclear Medicine. 22:21 24, 1997 |
43. Chitambar CR, Zahir, SA, Ritch PS, and Anderson T. Evaluation of continuous infusion gallium nitrate and hydroxyurea in combination for the treatment of refractory non-Hodgkin's lymphoma. American Journal of Clinical Oncology, 20:173-178, 1997 |
44. Chitambar CR and Wereley JP. Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1 and decreased ferritin production. Journal of Biological Chemistry, 272:12151- 12157, 1997. |
45. Chitambar CR and Wereley JP. Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells. Blood 91:4686-4693, 1998. |
46. Knorr GM, and Chitambar CR. Gallium-pyridoxal isonicotinoyl hydrazone (Ga-PIH), a novel cytotoxic gallium complex. A comparative study with gallium nitrate. Anti-Cancer Research 18:1733-1738, 1998. |
47. Myette, MS, Elford HL and Chitambar, CR. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase. Cancer Letters,129:199-204, 1998. |
48. Wong SJ, Myette MS*, Wereley JP and Chitambar CR. Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine. Clinical Cancer Research, 5:439 - 443, 1999. |
49. Chitambar CR, Wereley JP, Heinman T and O'Brien WJ. Cellular adaptation to downregulated iron transport: Effects on the expression of the gene for ribonucleotide reductase. Biochemical Journal, 345:681-685, 2000. |
50. Chitambar CR and Wereley JP. Iron transport in a lymphoid cell line with the hemochromatosis C282Y mutation. Blood, 97:2734-2740, 2001. |
51. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, and Chitambar CR. The anti-malarial artesunate is also active against cancer. International Journal of Oncology 18:767-773, 2001. |
52. Green DA, Antholine WE, Wong SJ, Richardson DR, and Chitambar CR. Inhibition of Malignant Cell Growth by 311, a Novel Iron Chelator of the Pyridoxal Isonicotinoyl Hydrazone Class: Effect on the R2 subunit of Ribonucleotide Reductase. Clinical Cancer Research,7:3574-3579, 2001. |
53. Kotamraju, S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - Role of oxidant-induced iron signaling in apoptosis. Journal of Biological Chemistry. 277:1719-1787, 2002. |
54. Chang C-C, Bunyi-Teopengco E, Eshoa C, Chitambar C, and Kamplath B. CD5 expression in neoplastic B-cells in T-cell/histiocyte-rich large B-cell lymphoma. Modern Pathology,15:1051-1057, 2002. |
55. Efferth T, Verdorfer I, Miyachi H, Sauerbrey A, Drexler HG, Chitambar CR, Haber M, and Gebhart E. Genomic imbalances in drug-resistant T-cell acute lymphoblastic CEM leukemia cell lines. Blood Cells, Molecules and Diseases, 29:1-13, 2002. |
56. Carroll,MC, FlemingM, Chitambar CR, Neuburg M. Diagnosis, workup, and prognosis of cutaneous metastases of unknown primary origin. Dermatol.Surg. 28:533-535, 2002 |
57. Chang C-C, Lorek J, Sabath DE, Li Y, Chitambar CR, Logan B, Kamplath B, and Cleveland RP. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood. 100:4671-4675,2002. |
58. Tampo Y, Kotaraju S, Chitambar CR, Keszler A, Joseph J, and Kalyanaraman B. Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells - The role of transferrin receptor-dependent iron uptake in apoptosis. Circulation Research, 92:56-63, 2003. |
59. Chitambar CR. Gallium nitrate revisited. Seminars in Oncology 30: 1-4, 2003. |
60. Chitambar CR and Wereley JP. Expression of the Hemochromatosis (HFE) gene modulates the cellular uptake of 67Ga. Journal of Nuclear Medicine 44:943-946, 2003. |
61. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL and Kalynaraman B. Nitric oxide inhibits peroxide-induced transferrin receptor dependent iron uptake, oxidative damage and apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 100:10653-10658, 2003. |
62. Efferth, T., Sauerbrey, A., Steinbach, D., Gebhart, E., Drexler, H. G., Miyachi, H., Chitambar, CR, Becker, CM, Zintl, F, and Humeny, A. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int.J.Oncol., 23: 509-517, 2003. |
63. Susnik B, Jordi Rowe J, Redlich PN, Chitambar CR, Chang CC, and Kampalath B. A unique collision tumor in breast: invasive ductal carcinoma and mucosa-associated lymphoid tissue lymphoma. Arch.Pathol.Lab Med. 128:99 - 101, 2004. |
64. Kampalath B, Abed N, Chitambar CR, Vantuinen P, Chakrabarty G, Hanson G, Rao RN, Shidham VB and Chang CC. Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: a diagnostic and treatment dilemma. Leukemia and Lymphoma, 45:409-414, 2004. |
65. Kotamraju S, Kavlivendi SV, Konorev E, Chitambar CR, Joseph J and Kalyanaraman B. Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. Methods in Enzymology 378:362-382, 2004. |
66. Kotamraju S, Tampo Y, Kalivendi SV, Joseph J, Chitambar CR, and Kalyanaraman B. Nitric oxide mitigates perioxide-induced iron signaling, oxidative damage, and apoptosis in endothelial cells: Role of proteosomal function? Archives of Biochemistry and Biophysics, 423:74-80, 2004. |
67. Chitambar CR. Gallium nitrate for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Investigational Drugs, 13:531-541, 2004. |
68. Chitambar CR. Gallium compounds as antineoplastic agents. Current Opinion in Oncology, 16: 547-552. 2004 |
69. Chitambar CR. Apoptotic mechanisms of gallium nitrate. Basic and clinical investigations. Oncology 18: 29-44, 2004. |
70. Davies NP, Rahmanto S, Chitambar CR, and Richardson DR. Resistance to gallium results in marked alterations in intracellular iron and gallium trafficking: Identification of novel intermediates Journal of Pharmacology and Experimental Therapeutics. 317:163-172, 2006. |
71. Chitambar CR, Kotamraju S, and Wereley JP. Expression of the Hemochromatosis Gene (HFE) Modulates the Cytotoxicity of Doxorubicin in Breast Cancer Cells. International Journal of Cancer 119:2200-2204, 2006. |
72. Chitambar CR. Wereley JP, and Matsuyama S. Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Molecular Cancer Therapeutics. 5:2834-2843, 2006. |
73. Yang M, Kroft SH, and Chitambar CR. Gene expression analysis of gallium-resistant and -sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Molecular Cancer Therapeutics. 6:633-43,2007. |
74. Bommakanti S, Patil A, Eshoa C, and Chitambar CR. Efalizumab-associated lymphoproliferative disease. Journal of Drugs in Dermatology: 6:25-27, 2007. |
75. Chitambar CR, Purpi DP, Woodliff J, Yang M, and Wereley JP. Gallium maltolate: a novel hydroxypyrone gallium compound with antineoplastic activity against lymphoma cells resistant to gallium nitrate. Journal of Pharmacology and Experimental Therapeutics,322:122-1236, 2007. |
76. Kolesar JM, Schelman WR, Geiger PG, Holen KD, Traynor AM, Alberti DB, Thomas JP, Chitambar CR, Wilding G, Antholine WE. Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with triapine. Journal of Inorganic Biochemistry. 30, 2007. Epub, ahead of print. 2008 Apr;102(4):693-8Oct. |
77. Yang M, and Chitambar CR. Role of oxidative stress in the induction of metallothionein-2A and heme oxygenase-1 gene expression by the antineoplastic agent gallium nitrate in human lymphoma cells. Free Radical Research & Medicine, 45:763-772, 2008. PMCID: PMC2610863 http://dx.doi.org/10.1016/j.freeradbiomed.2008.05.031 |
78. Chitambar, CR, and Purpi DP. A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells. Leukemia Research,34:950-953, 2010. |
79. Chitambar CR. Medical applications and toxicities of gallium compounds. Int. J. Environ. Res. Public Health, 7, 2337-2361, 2010. PMCID: PMC2610863 |
80. Yao X, Saad Y, Chitambar CR. Intravascular large B-cell lymphoma, an exclusively small vessel disease? A case report and review of literature. Leukemia Research, e275-e277, 2010. |
81. Chitambar CR. Apoptotic mechanisms of gallium nitrate. Encyclopedia of Metalloproteins, in press 2011. |
82. Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC. A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. J Cancer. 2012;3:145-51. PMCID: PMC3319980 |
83. Chitambar CR. Gallium-containing anticancer compounds. Future Med Chem. 2012 Jun;4(10):1257-72. PMCID: PMC3574811 |
84. Chitambar CR, Antholine WE. Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes. Antioxid Redox Signal. 2013 Mar 10;18(8):956-72. PMCID: PMC3557436 |
85. Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, Johnson B, Dwinell MB, Chitambar CR, Chen G. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. Stem Cells. 2015 Sep;33(9):2738-47. PMCID: PMC4792188 |
86. Wu X, Wang TW, Lessmann GM, Saleh J, Liu X, Chitambar CR, Hwang ST. Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice. J Invest Dermatol. 2015 Mar;135(3):877-884. |
87. Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP. Acid ceramidase confers radioresistance to glioblastoma cells. Oncol Rep. 2017 Oct;38(4):1932-1940. PMCID: PMC5652937 |
88. Chitambar CR. The therapeutic potential of iron-targeting gallium compounds in human disease: From basic research to clinical application. Pharmacol Res. 2017 Jan;115:56-64. |
89. Chitambar CR. Gallium and its competing roles with iron in biological systems. Biochim Biophys Acta. 2016 Aug;1863(8):2044-53. |
90. Herath K, Peswani N, Chitambar CR. Impact of obesity and exercise on chemotherapy-related fatigue. Support Care Cancer. 2016 Oct;24(10):4257-62. |
91. Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol Oncol Stem Cell Ther. 2016 Jun;9(2):48-54. |
92. Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP. Acid ceramidase and its inhibitors: a <i>de novo</i> drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. Oncotarget. 2017 Dec 22;8(68):112662-112674. PMCID: PMC5762539 |
93. Chitambar CR. Gallium Complexes as Anticancer Drugs. Met Ions Life Sci. 2018 Feb 05;18. |
94. Chitambar CR, Al-Gizawiy MM, Alhajala HS, Pechman KR, Wereley JP, Wujek R, Clark PA, Kuo JS, Antholine WE, Schmainda KM. Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. Mol Cancer Ther. 2018 Jun;17(6):1240-1250. PMCID: PMC5984712 |
95. Doan NB, Nguyen HS, Alhajala HS, Jaber B, Al-Gizawiy MM, Ahn EE, Mueller WM, Chitambar CR, Mirza SP, Schmainda KM. Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model. Oncotarget. 2018 May 04;9(34):23532-23542. PMCID: PMC5955095 |
96. Chaudhary LN, Jawa Z, Hanif A, Szabo A, Kamaraju S, Cheng YC, Chitambar CR. Does Progesterone Receptor Matter in the Risk of Recurrence for Patients With Ductal Carcinoma in Situ? WMJ. 2018 Jun;117(2):62-67. |
97. Doan N, Patel M, Nguyen HS, Doan H, Shabani S, Gelsomino M, Mountoure A, Janich K, Chitambar CR. Methotrexate-induced Leukoencephalopathy without Typical Restricted Diffusion on Diffusion-weighted Imaging and the Utility of Magnetic Resonance Spectroscopy to Support the Diagnosis. Asian J Neurosurg. 2018;13(3):848-850. PMCID: PMC6159078 |
98. Alhajala HS, Nguyen HS, Shabani S, Best B, Kaushal M, Al-Gizawiy MM, Erin Ahn EY, Knipstein JA, Mirza S, Schmainda KM, Chitambar CR, Doan NB. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy <i>via</i> genome-wide transcriptome changes. Oncotarget. 2018 Sep 25;9(75):34122-34131. PMCID: PMC6183347 |
99. Kapke JT, Schneidewend RJ, Jawa ZA, Huang CC, Connelly JM, Chitambar CR. High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature. Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):189-193. |
100. Alhajala HS, Nguyen HS, Shabani S, Best B, Kaushal M, Al-Gizawiy MM, Ahn EYE, Knipstein JA, Mirza S, Schmainda KM, Chitambar CR, Doan NB. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy via genome-wide transcriptome changes Oncotarget. 1 September 2018;9(75):34122-34131. |
101. Chitambar CR, Antony AC. Hematologic aspects of iron deficiency and less common nutritional anemias Modern Nutrition in Health and Disease: Eleventh Edition. 22 December 2012:1372-1384. |
102. Reddy GK, Chitambar CR, Jain VK. Activity of gallium nitrate in patients with refractory lymphoma Clinical Lymphoma. June 2004;5(1):17-18. |
103. Susnik B, Jordi Rowe J, Redlich PN, Chitambar C, Chang CC, Kampalath B. A unique collision tumor in breast: invasive ductal carcinoma and mucosa-associated lymphoid tissue lymphoma. Arch Pathol Lab Med. 2004 Jan;128(1):99-101. |
104. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Apr 01;83(7):1980-7. |
105. Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, Kalyanaraman B. Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. Oncotarget. 2019 May 28;10(37):3518-3532. PMCID: PMC6544408 |
106. Kaplinsky C. Effect of transferrin-gallium on leukemic cells. Blood. 1989 Aug 01;74(2):887-8. |
107. Bunin NJ, Casper JT, Chitambar C, Hunter J, Truitt R, Menitove J, Camitta BM, Ash R. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol. 1988 Dec;6(12):1851-5. |
108. Hansen R, Quebbeman E, Ritch P, Chitambar C, Anderson T. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci. 1988 Feb;295(2):91-3. |
109. Seligman PA, Chitambar C, Vostrejs M, Moran PL. The effects of various transferrins on iron utilization by proliferating cells. Ann N Y Acad Sci. 1988;526:136-40. |
110. Farrell NP, Gorle AK, Peterson EJ, Berners-Price SJ. Metalloglycomics. Met Ions Life Sci. 2018 Feb 05;18. |
111. Alhajala HS, Markley JL, Kim JH, Al-Gizawiy MM, Schmainda KM, Kuo JS, Chitambar CR. The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1. Oncotarget. 2020 Apr 28;11(17):1531-1544. PMCID: PMC7197450 |
112. Kaul M, Alhajala H, Chitambar CR, Chauhan A. Dendrimer–didox nanocomplex for enhanced anticancer activity Journal of Nanoparticle Research. 1 April 2020;22(4). |
113. Arispe Angulo KR, Jawa Z, Visotcky A, Majidi SS, Chitambar CR, Jorns JM. A high mitotic score in breast cancer after neoadjuvant chemotherapy is predictive of outcome and associated with a distinct morphology. Histopathology. 2020 Apr;76(5):661-670. |
114. Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. 2020 Sep 01;6(9):1410-1415. PMCID: PMC7349081 |
Books, Chapters, and Reviews |
1. Seligman PA, Chitambar CR, and Massey EJ: Structure and regulation of the transferrin receptor. In: Frontiers in Biochemical and Biophysical Studies of Proteins and Membranes, T. Eh-Yung Liu, ed. Amsterdam/Elesvier-Holland, p. 443-45l, l983. |
2. Seligman PA, and Chitambar CR: Effect of different transferrin-metal forms on both cellular iron metabolism and proliferation. In: Proteins of Iron Storage and Transport, Spik G, Montreauil J, Crichton RR, Mazurier J, eds. Elsvier Amsterdam l985, p. l23-l30. |
3. Ash RC, Casper J, Menitove J, Chitambar CR, Hansen R, Lum L, Lawton C, Murray K, Hunter K, Anderson T, and Camitta B. Evolving role of the closely HLA-matched unrelated marrow donor for alternative donor transplantation. In, Bone Marrow Transplantation: Current Controversies. Gale, R.P. and Champlin, R. (editors). Alan R. Liss, Inc. p. 629-640, 1989. |
4. Antholine WE, Narasimhan J*, Chitambar CR and Petering DH. Comparison of oxidative damage and inhibition of Fe uptake in HL60 cells from a mono or bis thiosemicarbazone copper complex. In, The Molecular Basis of Oxidative Damage by Leukocytes. Jesaitis, A.J., Dratz, E.A., eds. CRC Press, Boca Raton, p 307 -309, 1992. |
5. Chitambar CR, Anderson T, Hosenpud JR, Gottschall J. Hematologic Disorders. Part IX, Hematologic Disorders. Chapters 127 - 146; pages 576 - 635 in Kochar's Concise Textbook of Medicine, 4th edition. Kutty K, Schapira RM, Van Ruiswyk J, and Kochar MS eds. Lippincott, Williams and Wilkins, 2003. |
6. Anderson T and Chitambar CR and Hosenpud JR. Oncology. Part XIII, Chapters 197 - 214, pages 804 - 870, in Kochar's Concise Textbook of Medicine, 4th edition. Kutty K, Schapira RM, Van Ruiswyk J, and Kochar MS eds. Lippincott, Williams and Wilkins. 2003 |
7. Kajdacsy-Balla AA, Kaul S, Chitambar C, Lindholm P: The effect of iron on prostate and Breast cancer cells invasion. In: Metal Ions in Biology and Medicine, Khassanova L, Collery P, Maymard I, Khassanova Z, Etienne J-C, eds. John Libbey Eurotext, Paris. Vol.7, 617-620, 2002. |
8. Chitambar CR. Gallium nitrate-based therapy in a patient with relapsed non-Hodgkin's lymphoma. Case Studies in Lymphoma. Vol 2 (8), October 2003. |
9. Gregory SA, Chitambar CR, Hagemeister F and Strauss D. (Monograph). Expert Opinions in Oncology Series - "Promising New Therapies for the Treatment of Non-Hodgkin's Lymphoma". Annenberg Center for Health Sciences at Eisenhower, 2004. |
10. Chitambar CR, and Antony AC. "Nutritional Aspects of Hematologic Diseases", Chapter 92, in Modern Nutrition in Health and Disease, Shils MD, Shike M, Ross CA, Caballero B, and Cousins RJ, eds. Lippincott, Williams and Wilkins. 10th edition. 2005. pages 1436 - 1461. |
11. Chitambar CR. Cellular iron metabolism: mitochondria in the spotlight. Blood Capsule (editorial). Blood 105:1844-1845, 2005. |
12. Chitambar CR. Oncology Section editor, Kochar's Clinical Medicine for Students, 5th edition. |
13. Chitambar CR, and Antony AC. "Hematologic Aspects of Iron Deficiency and Less Common Nutritional Anemias", in Modern Nutrition in Health and Disease, Shils MD, Shike M, Ross CA, Caballero B, and Cousins RJ, eds. Lippincott, Williams and Wilkins. 11th edition. 2011, in press. |
Abstracts |
1. Chitambar CR, Massey EJ, and Seligman PA: Expression of the transferrin receptor on promyelocytic leukemia cells (HL60) during proliferation and dimethyl sulfoxide induced differentiation. American Federation for Clinical Research, Washington D.C., April, l983. Clinical Research 3l:3l0A, l983. |
2. Levine JS, Magree L, Chitambar CR, and Seligman PA: The ultrastructural immunocytochemical localization of the transferrin receptor (TFR) in human erythroleukemia cells (K562). American Federation for Clinical Research, April l983. Clinical Research 3l:3l7A. |
3. Chitambar CR, Glode LM, Robinson WA, and Lehman J: Low dose 5-azacytidine therapy in leukemia. American Association for Cancer Research (AACR), San Diego, CA, May, l983. AACR Proceedings 24:299, l983. |
4. Miller YE, Seligman PA, Chitambar CR, and Jones C: Biochemical characterization of a mutant human transferrin receptor. American Federation for Clinical Research, Carmel, CA, February, l984. Clinical Research 32:29A, l984. |
5. Chitambar CR and Seligman PA. Transferrin-gallium (Tf-Ga) decreases cellular iron uptake prior to inhibition of cellular proliferation. Blood 64:359A, l984. |
6. Chitambar CR, Zivkovic Z, and Abrams RA: Effect of gallium on hemoglobin production. ASCO meetings, May 1986, Proceedings of the American Society of Clinical Oncology 5:44, l986. |
7. Chitambar CR, Craig A, and Ash RC. Transferrin-gallium (Tf-Ga) inhibits hematopoietic progenitor cell proliferation in vitro by interfering with cellular iron utilization. Blood 68:l62A, l986. |
8. Bratanow NC*, Ash RC, Turner PA, Smith R, Chitambar C, Hansen R, and Casper J. Successful treatment of serious cytomegalovirus disease with 9 (l,3-dihydroxy-2 propoxymethyl guanine in bone marrow transplant (BMT) patients. Presented at the 28th Annual meeting of the American Society of Hematology, Dec. 1986. Blood 68:280A, l986. |
9. Chitambar CR and Zivkovic Z. Support of human leukemic cell growth by iron-pyridoxal isonicotinoyl hydrazone. Effects on ferritin production and transferrin receptor expression. Presented at the Eight International Conference on Proteins of Iron Transport and Storage. Montebello, Canada, May l2, l987. |
10. Chitambar CR, Lum LG, and Seigneuret MC**: Transferrin-gallium inhibits mitogen-stimulated proliferation of peripheral blood lymphocytes and blocks T lymphocyte-dependent immunoglobulin production. Presented at the 29th Annual meeting of the American Society of Hematology in Washington, D.C. in December, 1987. Blood 70:99A, 1987. |
11. Matthaeus WG*, Antholine WE, and Chitambar CR: Transferrin-gallium decreases the activity of ribonucleotide reductase and acts synergistically with hydroxyurea to inhibit the proliferation of human leukemic HL60 cells." Presented at the American Society of Hematology meetings in Washington, D.C. in December, 1987. Blood 70:264A, 1987. |
12. Ash RC, Menitove J, Casper J, Chitambar C, Hansen R, Bratanow N*, Lum L, Anderson T, Bunin N, Camitta B, Truitt R, Hunter J, and Aster R: Successful allogeneic marrow transplantation utilizing HLA-closely matched unrelated donors. Presented at the American Society of Hematology meetings in Washington, D.C. in December, 1987. Blood 70:289A, 1987. |
13. Bratanow N*, Turner P, Smith R, Chitambar C, Hansen R, Casper J, and Haasler G: The use of 9(1,3,-dihydroxy-2-propoxymethyl) guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in the treatment of serious cytomegalovirus (CMV) infections in thirty-one allogeneic bone marrow transplant (BMT) patients. Presented at the American Society of Hematology meetings in Washington, in December, 1987. Blood 70:302A, 1987. |
14. Nilius AM, Chitambar, CR, and Farmer SG: The response of pathogenic Aspergillus fumigatus to human transferrin. Presented at the American Society of Microbiology Annual meeting. May 1988. |
15. Chitambar, CR, and Zivkovic, Z: Release of soluble transferrin receptor from the surface of HL60 cells. Presented at the 30th Annual meeting of the American Society of Hematology in San Antonio, TX. December 1988. Blood 72:37A, 1988. |
16. Ash RC, Casper J, Hansen R, Chitambar C, Baxter-Lowe LA, Hunter J, Lawton C, Murray K, Truitt R, Camitta B, Anderson T, Menitove J. Successful marrow transplantation from closely HLA-matched unrelated donors. Presented at the 31st Annual meeting of the American Society of Hematology in Atlanta GA. December 1989. Blood 74:122A, 1989. |
17. Ash RC, Casper J, Lawton C, Hansen R, Chitambar C, Murray K, Camitta B, Anderson T, Truitt R. "Third generation" T depletion GVHD prophylaxis in genotypically HLA-matched sibling marrow transplantation: Durable engraftment with apparent preservation of the graft-versus-leukemia (GVL) effect. Presented at the 31st Annual meeting of the American Society of Hematology in Atlanta GA. December 1989. Blood 74:608A, 1989. |
18. Lundberg JH, Matthaeus WG* and Chitambar CR. Gallium nitrate and fludarabine in combination synergistically inhibit the proliferation of human leukemic HL60 cells. Proceedings of the American Society of Clinical Oncology 9:77, l990. |
19. Chitambar CR, Zivkovic-Gilgenbach Z, and Narasimhan J* Development of drug resistance to gallium nitrate through modulation of transferrin receptor expression and iron uptake. Proceedings of the American Association for Cancer Research, Washington, D.C. 31:362, 1990. |
20. Antholine WE, Narasimhan J, Chitambar CR, Petering DH. Comparison of oxidative damage and inhibition of Fe uptake in HL60 cells from a mono or bis thiosemicarbazone Cu complex. Presented at the UCLA symposium on "Molecular Basis of Oxidative Damage by Leukocytes" - Keystone Symposium on Molecular and Cellular Biology. J. Cellular Biochemistry Suppl. 15C, pg 216, 1991. |
21. Chitambar CR, and Noble NA. Shedding of transferrin receptor (TFR) from reticulocytes during maturation: soluble TFR is derived from TFR shed in vesicles. Presented at the 32nd Annual meeting of the American Society of Hematology in Boston, MA. December 1990. Blood 76:27A, 1990. |
22. Chitambar, CR and Sax, D. Regulatory effects of gallium on transferrin (Tf)-independent iron uptake by HL60 cells. Presented at the 33rd Annual meeting of the American Society of Hematology in Denver, CO, December 1991. Blood 1991. |
23. Baxter-Lowe,L.A., Casper J., Flomenberg N., Dinauer D.,Camitta B., Drobyski W., Garbrecht F., Pietryga M., Horowitz M., Chitambar C, Hansen R, Bunin N., Keever C., Pierce K., Ash R. Impact of HLA disparity in bone marrow transplantation. American Association of Immunology, presented at the AAI/CIS joint meeting May 25, 1993. |
24. Drobyski, WR, Ash RC, Casper JT, McAuliffe, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T, Flomenberg N. Effect of T-cell depletion as graft-versus-host prophylaxis on engraftment, relapse and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Presented at the 35th Annual Meeting of the American Society of Hematology. Blood 82:423a, 1993. |
25. Chitambar CR and Wereley JP. Relationship of Ribonucleotide reductase activity to iron uptake and the regulation of transferrin receptor and ferritin expression in lymphoblastic leukemic CCRF-CEM cells. Presented at the 36th Annual Meeting of the American Society of Hematology. Blood 84:420a, 1994. |
26. Chitambar CR and Wereley JP. Relationship of Ribonucleotide reductase activity to iron uptake and the regulation of transferrin receptor and ferritin expression in lymphoblastic leukemic CCRF-CEM cells. Presented at the International Conference on BioIron. April 17-21, 1995, Asheville, N.C. |
27. Wong SJ, Wereley JP and Chitambar CR. Ribonucleotide reductase expression in mitogen-activated T lymphocytes: Relationship to iron transport, transferrin receptor, ferritin and DNA synthesis. Blood:124b, 1996. |
28. Drobyski WR, Ul-Haq R, Majeski D, Chitambar CR. Gallium nitrate inhibits T cell activation and experimental graft versus host disease in mice. Blood: 229b, 1996. |
29. Chitambar CR and Wereley JP. Drug resistance to the antineoplastic agent gallium nitrate is associated with decreased gallium/iron transport into cells, increased activity of iron regulatory protein-1 and decreased ferritin synthesis. Presented at the 38th Annual Meeting of the American Society of Hematology, Dec 1996. Blood: 88:363a, 1996. |
30. Wong,SJ, Myette M and Chitambar CR. Supersensitivity to gemcitabine in hydroxyurea-resistant human leukemic CCRF-CEM cells. Presented at the 89th annual meeting of the American Association for Cancer Research. New Orleans, March 1998. Cancer Research, Vol 39:217, Abstract 1482, 1998. |
31. Chitambar CR, Wereley J, Tsao L and O'Brien. Iron proteins as targets to modulate tumor cell growth. New insights into the cytotoxicity of gallium- a modulator of iron metabolism. Proceedings of the 6th Internet World Congress on Biomedical Sciences 2000 at Castilla La Mancha University Spain. 2000. Available from URL: http://www.uclm.es/inabis2000/symposia/files/141/index.htm. |
32. Carroll MC, Fleming M, Chitambar CR and Neuberg M. Metastatic adenocarcinoma of unknown primary presenting as a subcutaneous mass. Presented at the American College of Mohs Micrographic Surgery and Cutaneous Oncology, Denver CO, November 2-5, 2000. |
33. Green, D.A., Antholine, W.E., Richardson, D.R. and Chitambar, C.R. Ribonucleotide reductase as a preferential target for the inhibition of leukemic cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class. Proceedings of the Bioiron 2001 World Congress on Iron Metabolism, Cairns, Australia, August 18-23 2001. |
34. Wong S.J., Chang, C-C, Revolinski J, and Chitambar CR. Radiosensitizing effects of gallium are modulated by expression of R2 subunit of ribonucleotide reductase. Presented at the 93rd Annual meeting of the American Association for Cancer Research, San Francisco, CA April 2002. AACR 43:483, Abstract 2404, 2002. |
35. Kajdacsy-Balla AA, Kaul S, Chitambar CR, and Lindholm P. Iron exposure causes an increase in cancer cell invasion and motility. Presented at the 93rd Annual meeting of the American Association for Cancer Research, San Francisco CA. April 2002. Proc AACR 43:1044, Abstract 5171, 2002. |
36. Chang C-C, Chitambar CR, Revolinski J, Purpi D, Schur BC, and Wong SJ. Measurement of ribonucleotide reductase R2 subunit expression by one-stpe multiplex real-time quantitative RT-PCR. Presented at the 93rd Annual meeting of the American Association for Cancer Research, San Francisco, CA April 2002. Proc AACR 43:907, Abstract 4497, 2002. |
37. Efferth T, Dunstan H, Weber HL, Rausch RP, Sauerbrey A, Miyachi H, Chitambar CR, Funk JO. The antimalarial artesunate is also active against cancer. 6th World Congress on Advances in Oncology and 4th International Symposium on Molecular Medicine. October 18-20, 2001. Crete, Greece. |
38. Efferth T, Verdorfer I, Sauerbrey A, Miyachi H, Chitambar CR, Drexler HG, Gebhart E. Genomic gain and loss associated with drug-resistance of CCRF-CEM leukemic cells. Presented at Cancer Detection and Prevention 6th International Symposium, Paris, France February 9-12, 2002. |
39. Chitambar CR, Kotamraju S, Kalayanaraman B, Wereley JP. Expression of the hemochromatosis (HFE) gene decreases doxorubicin-induced oxidative stress and apoptosis in MCF-7 breast cancer and endothelial cells. Blood 201:Abstract 3727. 2003 |
40. Schlicht M, Wereley JP, Datta MW, Chang CC, Hessner MJ and Chitambar CR. Identification of biomarkers for tumor sensitivity and resistance to the antineoplastic drug gallium nitrate in nonHodgkin's lymphoma. Presented at the American Association for Cancer Research 94th annual meeting in Washington DC. July 2003. |
41. Saleh MN, Burton IG, Hargis JB, Chitambar C, Jones CM, Shapiro CL, Homlund JT, Dorr FA. Phase 2 trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with weekly paclitaxel in the treatment of patients with metastatic breast cancer. Presented at the 39th Annual meeting of the American Society of Clinical Oncology 2003, Chicago. Proc ASCO 22:207, Abstract 829, 2003. |
42. Chitambar CR, Wereley JP, and Matsuyama S. Mechanisms of antineoplastic activity of gallium nitrate in lymphoma: Protein ubiquitination and the induction of apoptosis through a Bax and mitochondrial pathway. Presented at the American Association for Cancer Research 95th Annual meeting, Orlando, Florida. AACR Proc, Volume 45: Abstract 5317, 2004. |
43. Schlicht M, Kaul S, Datta MW, Hessner M, Chitambar CR, Kajdacsy-Balla AA. Genomic profiling identifies genes and pathways involved in the iron-induced prostate cancer cell invasive phenotype. Presented at the American Association for Cancer Research 95th Annual meeting, Orlando, Florida. AACR Proc, Volume 45: 1322, Abstract 5051, 2004. |
44. Imkie, MM, Chitambar CR, Kampalath B, Datta M, Dincer AP, Change CC. CD71 expression in diffuse large B-cell lymphoma, Mod Pathol,17:253A; 2004 |
45. Pro B, Bociek RG, Chitambar CR, Gregory SA, Leonard JP, Smith S, Novick S. Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL). Presented at the American Society of Hematology 46th annual meeting in San Diego, CA. 2004. Blood 104:682a, (Abstract 2487), 2004. |
46. Joseph T, Wereley JP and Chitambar CR. Gallium nitrate as a novel agent for the treatment of mantle cell lymphoma: Targets and mechanisms of action. Presented at the 96th Annual AACR meeting in Anaheim CA, April 16 - 20, 2005. AACR Proceedings Vol 46: 1383-1384, Abstract 5879. |
47. Chitambar CR, Joseph T, Marable D, and Wereley JP. Development of gallium compounds for the treatment of non-Hodgkin's lymphoma: Gallium maltolate as a novel agent with broad-spectrum activity against diverse lymphoma cell types. Presented at the 97th Annual AACR meeting in Washington, DC, April 1- 5, 2006. AACR Proceedings Vol. 47. Abstract 5464. |
